| 2025-12-11 |
详情>>
内部人交易：
D'Silva Andrew J.等共交易2笔
|
| 2025-11-07 |
详情>>
股本变动：
变动后总股本1864.07万股
|
| 2025-11-07 |
详情>>
业绩披露：
2025年三季报(累计)每股收益0.01美元,归母净利润11.20万美元,同比去年增长100.56%
|
| 2025-11-06 |
财报披露：
美东时间 2025-11-06 盘后发布财报
|
| 2025-08-08 |
详情>>
业绩披露：
2025年中报每股收益-0.04美元,归母净利润-66.7万美元,同比去年增长93.89%
|
| 2025-05-13 |
详情>>
业绩披露：
2025年一季报每股收益-0.12美元,归母净利润-219.9万美元,同比去年增长68.13%
|
| 2025-04-30 |
股东大会：
将于2025-06-11召开股东大会
会议内容 ▼▲
- 1.Election as directors, the five persons named in the accompanying proxy statement as our Board of Directors’ nominees to serve on our Board until our 2026 Annual Meeting and until their successors are duly elected and qualified or until their earlier death, resignation, or removal.
2.Advisory (non-binding) approval of the compensation of OptimizeRx’s named executive officers.
3.Ratification of UHY LLP as OptimizeRx’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
4.Consideration of any other business properly brought before the Annual Meeting or any postponements or adjournments thereof.
|
| 2025-03-20 |
详情>>
业绩披露：
2024年年报每股收益-1.1美元,归母净利润-2011万美元,同比去年增长-14.48%
|
| 2025-03-12 |
复牌提示：
2025-03-12 09:42:21 停牌，复牌日期 2025-03-12 09:47:21
|
| 2024-11-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.1美元,归母净利润-2003.2万美元,同比去年增长-49.22%
|
| 2024-08-15 |
详情>>
业绩披露：
2024年中报每股收益-0.6美元,归母净利润-1090.8万美元,同比去年增长-3.3%
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益-0.38美元,归母净利润-689.9万美元,同比去年增长-7.83%
|
| 2024-04-29 |
股东大会：
将于2024-06-05召开股东大会
会议内容 ▼▲
- 1.Election of six directors, as described in the accompanying proxy statement.
2.Advisory approval of the compensation of OptimizeRx’s named executive officers.
3.Amendment to OptimizeRx Corporation 2021 Equity Incentive Plan to increase the aggregate number of shares of common stock available for awards by 1,950,000 shares to 4,450,000 shares.
4.Ratification of UHY LLP as OptimizeRx’s independent registered public accounting firm for the 2024 fiscal year.
5.Consideration of any other business properly brought before the annual meeting.
|
| 2024-04-15 |
详情>>
业绩披露：
2023年年报每股收益-1.03美元,归母净利润-1756.59万美元,同比去年增长-53.57%
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.79美元,归母净利润-1342.45万美元,同比去年增长-20.8%
|
| 2023-08-14 |
详情>>
业绩披露：
2023年中报每股收益-0.62美元,归母净利润-1055.92万美元,同比去年增长-38.1%
|
| 2023-04-25 |
股东大会：
将于2023-06-07召开股东大会
会议内容 ▼▲
- 1.Election of six directors, as described in the accompanying proxy statement.
2.Advisory approval of the compensation of OptimizeRx’s named executive officers.
3.Ratification of UHY LLP as OptimizeRx’s independent registered public accounting firm for the 2023 fiscal year.
4.Consideration of any other business properly brought before the annual meeting.
|
| 2022-04-25 |
股东大会：
将于2022-06-09召开股东大会
会议内容 ▼▲
- 1.Election of six directors, as described in the accompanying proxy statement.
2.Advisory approval of the compensation of OptimizeRx’s named executive officers.
3.Ratification of UHY LLP as OptimizeRx’s independent registered public accounting firm for the 2022 fiscal year.
4.Consideration of any other business properly brought before the annual meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-07-08 |
股东大会：
将于2021-08-19召开股东大会
会议内容 ▼▲
- 1.Election of six directors, as described in the accompanying proxy statement.
2.Advisory approval of the compensation of OptimizeRx’s named executive officers.
3.Advisory approval of the frequency of the advisory vote on named executive officer compensation.
4.Approval of the OptimizeRx Corporation 2021 Equity Incentive Plan.
5.Ratification of UHY LLP as OptimizeRx’s independent registered public accounting firm for the 2021 fiscal year.
6.Consideration of any other business properly brought before the annual meeting.
|
| 2020-10-01 |
股东大会：
将于2020-11-19召开股东大会
会议内容 ▼▲
- 1.To elect six members to the Board of Directors of the Company to serve until their respective successors are elected and qualified;
2.To approve the reservation of 500,000 additional shares of common stock under our 2013 Incentive Plan;
3.To ratify the appointment of UHY LLP as our independent public accountant for the fiscal year ended December 31, 2020;
4.To transact such other matters as may properly come before the meeting or any adjournment thereof.
|
| 2019-09-24 |
股东大会：
将于2019-11-04召开股东大会
会议内容 ▼▲
- 1.Election of five directors to serve on the Company’s board of directors until the 2020 annual meeting of stockholders or until their successors are elected and qualified;
2.To approve the OptimizeRx Corp. 2013 Equity Incentive Plan and the reserve of 2,500,000 shares of common stock under the Plan;
3.To ratify the appointment of Marcum LLP as our independent public accountant for the fiscal year ending December 31, 2019;
4.To transact such other business as may be properly brought before the Annual Meeting and any adjournments thereof.
|